Ir directamente a la navegación principal Ir directamente a la búsqueda Ir directamente al contenido principal

Time Course of Kidney Injury Biomarkers in Children With Septic Shock: Nested Cohort Study Within the Pragmatic Pediatric Trial of Balanced Versus Normal Saline Fluid in Sepsis Trial

  • Scott L. Weiss
  • , Julie C. Fitzgerald
  • , Benjamin L. Laskin
  • , Ruchi Singh
  • , Amanda S. Artis
  • , Ananya Vohra
  • , Elena Tsemberis
  • , Emem Kierian
  • , Kristen C. Lau
  • , Atzael B. Campos
  • , Christopher Hickey
  • , Katie L. Hayes
  • , Daniel Singleton
  • , Elliot Long
  • , Franz E. Babl
  • , Stuart R. Dalziel
  • , Graham C. Thompson
  • , Stephen B. Freedman
  • , Michelle Eckerle
  • , Robert W. Hickey
  • Jing Huang, Nathan Kuppermann, Fran Balamuth
  • Thomas Jefferson University
  • The Children's Hospital of Philadelphia
  • Royal Children's Hospital
  • University of Melbourne
  • Murdoch Children's Research Institute
  • The University of Auckland
  • Auckland District Health Board
  • University of Calgary
  • Cincinnati Children's Hospital Medical Center
  • University of Pittsburgh
  • University of Pennsylvania
  • George Washington University

Producción científicarevisión exhaustiva

10 Citas (Scopus)

Resumen

Objective: Severe acute kidney injury (AKI) portends poor outcomes in pediatric sepsis. We evaluated the trajectory and prognostic utility of AKI biomarkers in pediatric septic shock using a subset of participants in the ongoing Pragmatic Pediatric Trial of Balanced vs. Normal Saline Fluid in Sepsis (PRoMPT BOLUS) trial, NCT04102371. We tested whether fluid volume is associated with persistent elevation of urine neutrophil gelatinase-associated lipocalin (Ur-NGAL). Design: Prospective, non-prespecified cohort study within the PRoMPT BOLUS trial. Setting: Three children's hospitals in the United States. Patients: Four hundred seventy-eight patients aged 2 months to younger than 18 years old with septic shock. Interventions: None. Measurements and Main Results: Ur-NGAL, kidney injury molecule-1, liver fatty acid binding protein, and interleukin-18 and plasma cystatin C were collected at presentation (T1), days 2-3 (T2), and before discharge/death (T3). At presentation, 418 (88%) had no or only stage 1 AKI and 60 (12%) had stage 2/3 AKI defined using Kidney Disease Improving Global Outcomes creatinine thresholds. All biomarkers were higher with stage 2/3 compared with no/stage 1 AKI at T1 and T2, but only cystatin C remained higher at T3. Among patients with no/stage 1 AKI at presentation, those with Ur-NGAL greater than or equal to 150 vs. less than 150 ng/mL had fewer hospital-free days (21 [interquartile range (IQR) 15-24] vs. 23 d [IQR 19-25], p = 0.05). After applying inverse probability treatment weighting to balance covariates, 14% of patients who received greater than 100 mL/kg within 48 hours had persistently elevated Ur-NGAL over time compared with 6% who received 40-100 mL/kg (odds ratio 2.7 [95% CI, 1.1-6.2]). Hospital-free days were no different across fluid volume groups. Conclusions: Although kidney injury biomarkers mirrored serum creatinine in children with septic shock, elevated Ur-NGAL identified a subset with subclinical AKI with fewer hospital-free days despite no/stage 1 AKI by creatinine. Children receiving greater than 100 mL/kg fluid had greater odds of early and persistently elevated Ur-NGAL, suggesting high fluid volumes may perpetuate initial kidney damage.

Idioma originalEnglish
Número de artículo10.1097/PCC.0000000000003737
Páginas (desde-hasta)e816-e826
PublicaciónPediatric Critical Care Medicine
Volumen26
N.º6
DOI
EstadoPublished - 1 jun 2025

Huella

Profundice en los temas de investigación de 'Time Course of Kidney Injury Biomarkers in Children With Septic Shock: Nested Cohort Study Within the Pragmatic Pediatric Trial of Balanced Versus Normal Saline Fluid in Sepsis Trial'. En conjunto forman una huella única.

Citar esto